Tesamorelin before and after: the honest results timeline

Searching “tesamorelin before and after” usually turns up the same thing: a leaner, more muscular adult in a side-by-side photo, captioned as a few months of injections. Here is the honest version up front — tesamorelin (sold as Egrifta) has one result that real trials actually measured, and it is not a physique reveal. It is a reduction in visceral abdominal fat: the deep fat packed around your organs, the kind you can only see on an imaging scan. This page lays out what tesamorelin genuinely does over time, on what realistic timeline, and why the marketed “before and after” rarely matches the measured one. For the underlying approval and trial design, see our tesamorelin (Egrifta) evidence review.

What “before and after” actually means here

The honest before-and-after for tesamorelin is a number on an imaging report, not a photo. In the pivotal randomized, placebo-controlled trials — conducted in adults with HIV-associated lipodystrophy — the measured endpoint was the change in visceral adipose tissue, the deep fat surrounding the abdominal organs. Tesamorelin reduced that visceral fat versus placebo, and follow-up analyses tied that reduction to an improved metabolic profile.^[1][2] That is the authentic “after”: an internal measurement moving in people whose antiretroviral therapy had driven abnormal visceral-fat accumulation. It is real, it is documented, and it looks nothing like the body-recomposition montages the search term implies.

A realistic timeline: months, not weeks

The single most over-promised part of tesamorelin marketing is speed. The trial-proven effect is slow. Tesamorelin works indirectly — it prompts your pituitary to release your own growth hormone in pulses, which raises IGF-1, which over time nudges visceral fat down. That cascade takes months to produce a measurable change. In the pivotal program, the headline visceral-fat reduction was assessed at roughly 26 weeks of daily injections.^[1] There is no credible trial basis for expecting a meaningful, measured change in the first few weeks. Anyone showing you a dramatic two-week transformation is not showing you a tesamorelin result.

What it does not do — no muscle, no “leaner in the mirror”

Two claims dominate the before/after photos and neither has controlled-trial support for tesamorelin. First, it does not build muscle — the trials measured visceral fat, not lean-mass gains, and there is no body of randomized evidence showing tesamorelin produces the muscular “after” in those images. Second, it is not a subcutaneous fat-loss drug; the leaner-looking, more-defined physique people associate with “cutting” comes from losing the fat just under the skin, which is not what tesamorelin was shown to target. So when a transformation photo shows visible muscle and a tighter waist, it is showing changes tesamorelin was never demonstrated to cause — far more plausibly the product of diet, training, lighting, and photo selection running alongside the injections.

The evidence is in HIV lipodystrophy — everything else is extrapolation

It is worth being precise about where these results come from. Every figure above — the visceral-fat reduction, the ~26-week timeline, the reversal on stopping — was established in adults with HIV-associated lipodystrophy, the FDA-approved population.^[1][2]Off-label use for general fat loss, bodybuilding, or anti-aging in people without HIV rides on that data without its own outcome trials. That does not make the molecule fake; it means the realistic “before and after” you can point to was measured in a different population, for a specific condition. Extending it to a healthy-adult physique goal is an assumption, not a finding.

The honest bottom line

Tesamorelin has a genuine before-and-after — a reduction in visceral abdominal fat, measured by scan, over roughly three to six months of daily injections, in adults with HIV-associated lipodystrophy, and reversing once the drug is stopped.^[1][2] What it does not have is the fast, muscular, “leaner in the mirror” transformation that the search term hopes for: that result has no controlled trials behind it, targets a different kind of fat, and conflates the peptide with whatever diet and training happened alongside it. If what you are really asking is whether the injections deliver a dramatic makeover, the candid answer is that the published record can only promise an internal measurement — not a photo. For how it stacks up against a milder GHRH peptide, see our tesamorelin vs sermorelin comparison and the parallel honest read on sermorelin before and after. To compare the proof behind each peptide side by side, use our peptide evidence matrix, and if you are weighing a supervised program, start with our guide to peptide therapy. The sensible move is to bring the real, scan-based endpoint to a qualified clinician — rather than chasing a transformation photo lifted from a forum thread.